StockpollyBeta
Get App

Categories·Biotech

New Drug Development

Companies that use cell culture and genetic recombination to develop groundbreaking new drugs and export the underlying technology.

−0.01% today·581 stocks·3 sub-categories

Stocks

By market cap · 581 stocks

  1. 1ABBVAbbVieImmunology drugmaker behind Skyrizi, Rinvoq, and Botox$467.37B−0.71%
  2. 2MRKMerckMaker of Keytruda, vaccines, and animal medicines$369.24B−0.78%
  3. 3AZNAstraZeneca (ADR)Oncology-led developer of specialty medicines$260.70B−0.51%
  4. 4AMGNAmgenMaker of Prolia, Repatha, and rare-disease medicines$212.19B+2.66%
  5. 5GILDGilead SciencesDeveloper of HIV, liver-disease, and cancer medicines$186.93B−0.74%
  6. 6BMYBristol-Myers SquibbDeveloper of Eliquis, Opdivo and specialty medicines$127.91B−0.65%
  7. 7REGNRegeneronMaker of Dupixent, EYLEA HD, and Libtayo$82.23B−0.39%
  8. 8MRNAModernaDeveloper of mRNA vaccines and therapeutics$68.62B−0.25%
  9. 9ARGXargenx (ADR)Developer of VYVGART autoimmune medicines$61.45B−1.01%
  10. 10RVMDRevolution MedicinesDeveloper of RAS(ON) oncology candidates$40.98B−0.40%
  11. 11ONCBeOne Medicines (ADR)Developer of BRUKINSA and TEVIMBRA oncology medicines$39.07B−0.75%
  12. 12ALNYAlnylam PharmaceuticalsRNAi medicines built around gene-silencing delivery$32.69B+0.10%
  13. 13BIIBBiogenNeuroscience medicines across MS and rare disease$32.37B+0.50%
  14. 14ROIVRoivant SciencesVant-based developer of immunology medicines$28.17B−0.06%
  15. 15INSMInsmedTwo marketed pulmonary medicines and gene therapies$26.23B+0.12%
  16. 16RPRXRoyalty PharmaBuyer and funder of drug royalties$25.90B−0.60%
  17. 17INCYIncyteJakafi-led hematology, oncology, and immunology drug developer$25.27B−0.16%
  18. 18BNTXBioNTech (ADR)Comirnaty developer with an oncology pipeline$24.62B−0.15%
  19. 19GMABGenmab (ADR)Builder of antibody medicines and bispecific platforms$21.30B−0.49%
  20. 20UTHRUnited TherapeuticsMaker of Tyvaso and investigational organ alternatives$20.93B−0.38%
  21. 21JAZZJazz PharmaceuticalsSleep, epilepsy and oncology rare-disease medicines$15.17B−0.58%
  22. 22NBIXNeurocrine BiosciencesDeveloper of INGREZZA and rare-disease medicines$14.48B−0.08%
  23. 23EXELExelixisBuilder of the cabozantinib oncology franchise$14.38B+0.47%
  24. 24SMMTSummit TherapeuticsDeveloper of ivonescimab for solid tumors$13.48B+0.80%
  25. 25HALOHalozyme TherapeuticsENHANZE platform for subcutaneous drug delivery$13.22B−0.10%
  26. 26BBIOBridgeBio PharmaAttruby-led genetic disease drug developer$13.04B+0.36%
  27. 27BMRNBioMarinRare-disease therapies spanning enzymes and skeletal conditions$12.38B−0.21%
  28. 28MDGLMadrigal PharmaceuticalsMASH drug developer behind Rezdiffra$12.06B+0.20%
  29. 29BAXBaxter InternationalHospital infusion, connected-care, and injectable products$11.85B+2.18%
  30. 30AXSMAxsome TherapeuticsCNS medicines for depression, agitation, sleepiness, and migraine$10.57B−0.06%
  31. 31KRYSKrystal BiotechTopical VYJUVEK and redosable genetic medicine pipeline$9.84B+1.24%
  32. 32ARWRArrowhead PharmaceuticalsDeveloper of targeted RNAi medicines$9.69B−0.51%
  33. 33KYMRKymera TherapeuticsOral protein degraders for immunological diseases$9.68B+1.00%
  34. 34PTGXProtagonist TherapeuticsPeptide-drug developer behind ICOTYDE and rusfertide$9.32B−0.50%
  35. 35IBRXImmunityBioMaker of ANKTIVA and cellular immunotherapies$8.85B+1.66%
  36. 36TGTXTG TherapeuticsCommercializer of BRIUMVI for relapsing multiple sclerosis$8.75B+0.37%
  37. 37PCVXVaxcyteDeveloper of high-valency pneumococcal vaccines$8.51B+1.36%
  38. 38CYTKCytokineticsDeveloper of MYQORZO and cardiac muscle medicines$8.41B+1.16%
  39. 39PRAXPraxis Precision MedicinesPrecision neuroscience drug developer for tremor and epilepsy$8.33B+2.32%
  40. 40SYRESpyre TherapeuticsDeveloper of long-acting immunology antibody combinations$7.99B−0.01%
  41. 41IMVTImmunovantDeveloper of imeroprubart for autoimmune diseases$7.67B+1.80%
  42. 42ABVXAbivax (ADR)Developer of oral obefazimod for inflammation$7.60B−3.32%
  43. 43IONSIonis PharmaceuticalsAntisense medicines with owned and partnered launches$7.46B−0.18%
  44. 44BLTEBelite Bio (ADR)Developer of oral retinal-disease therapies$6.95B+1.25%
  45. 45CGONCG OncologyCretostimogene developer and contract manufacturer$6.90B+2.08%
  46. 46RYTMRhythm PharmaceuticalsMC4R therapies for rare neuroendocrine obesity$6.78B+0.69%
  47. 47GRFSGrifols (ADR)Integrated plasma therapies and diagnostics$6.23B+0.59%
  48. 48KNSAKiniksa PharmaceuticalsARCALYST marketer for recurrent pericarditis$5.95B−0.12%
  49. 49TVTXTravere TherapeuticsRare kidney-disease medicines led by FILSPARI$5.85B−1.77%
  50. 50LGNDLigand PharmaceuticalsBiopharmaceutical royalty aggregator with Captisol and NITRICIL$5.81B−0.24%